Pipeline

 

Program Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC)

58%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Primary Biliary Cholangitis

44%

Ralinepag (APD811)
Prostacyclin (IP) Receptor Agonist

Pulmonary Arterial Hypertension (PAH)

62%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Olorinab (APD371)
Highly Selective Full Agonist to CB2
Crohn’s Pain

41%

Arena: Worldwide
Partnered Programs
BELVIQ and BELVIQ XR Weight Loss Approved: CVOT Ongoing

98%

Eisai: Worldwide
Nelotanserin
5-HT2A Inverse Agonist
Visual Hallucinations in Lewy Body Dementia

50%

Axovant: Worldwide
REM Sleep Behavior Disorder in Dementia with Lewy Bodies

41%

Axovant: Worldwide
Undisclosed Orphan GPCR CNS

15%

Boehringer Ingelheim: Worldwide

Program Indication Phase Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) Ph2 Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Primary Biliary Cholangitis Ph2
Ralinepag (APD811) Prostacyclin (IP) Receptor Agonist
Pulmonary Arterial Hypertension (PAH) Ph2 Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories/td>
Olorinab (APD371) Highly Selective Full Agonist to CB2
Crohn’s Pain Ph2 Arena:
Worldwide
Partnered Programs
BELVIQ and BELVIQ XR Weight Loss Approved: CVOT Ongoing Market Eisai: Worldwide
Nelotanserin 5-HT2A Inverse Agonist Visual Hallucinations in Lewy Body Dementia Ph2 Axovant:
Worldwide
REM Sleep Behavior Disorder in Dementia with Lewy Bodies Ph2 Axovant:
Worldwide
Undisclosed Orphan GPCR CNS Pre-Clin Boehringer Ingelheim:
Worldwide